1. 7OPAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer. (13th May 2019) Authors: Prat, A; Tsai, Y-H; Pascual, T; Paré, L; Vidal, M; Adamo, B; Brase, J C; Johnston, S R D; Ciruelos, E M; Parker, J S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. (12th October 2017) Authors: Nuciforo, P; Pascual, T; Cortés, J; Llombart-Cussac, A; Fasani, R; Paré, L; Oliveira, M; Galvan, P; Martínez, N; Bermejo, B; Vidal, M; Pernas, S; López, R; Muñoz, M; Garau, I; Manso, L; Alarcón, J; Martínez, E; Rodrik-Outmezguine, V; Brase, J C Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. (27th August 2018) Authors: Paré, L; Pascual, T; Seguí, E; Teixidó, C; Gonzalez-Cao, M; Galván, P; Rodríguez, A; González, B; Cuatrecasas, M; Pineda, E; Torné, A; Crespo, G; Martin-Algarra, S; Pérez-Ruiz, E; Reig, Ò; Viladot, M; Font, C; Adamo, B; Vidal, M; Gaba, L Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. (18th February 2019) Authors: Guarneri, V; Dieci, M V; Bisagni, G; Frassoldati, A; Bianchi, G V; De Salvo, G L; Orvieto, E; Urso, L; Pascual, T; Paré, L; Galván, P; Ambroggi, M; Giorgi, C A; Moretti, G; Griguolo, G; Vicini, R; Prat, A; Conte, P F Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 921 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PD-031Immune signatures identify three immune clusters in mCRC, with potential clinical implications. (2nd July 2019) Authors: Pedrosa, L; Moreno, R; Esposito, F; Jares, P; Cuatrecasas, M; Pineda, E; Español, M; Paré, L; De la Iglesia, N; Benitez, D; Camps, J; Church, S; Cascante, M; Thomson, T; Prat, A; Maurel, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗